鼻咽癌细胞程序性死亡配体 1 和 BRAF 表达的表达及临床意义。
Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma.
机构信息
Department of Oncology, Kiang Wu Hospital, Macau, SAR, China.
Department of Pathology, Kiang Wu Hospital, Macau, SAR, China.
出版信息
BMC Cancer. 2019 Oct 29;19(1):1022. doi: 10.1186/s12885-019-6276-y.
BACKGROUND
The prognostic value of programmed death-ligand 1 (PD-L1) and BRAF expression in nasopharyngeal carcinoma (NPC) is not well-defined. In this study we investigated alterations in PD-L1, BRAF and EGFR by using immunohistochemistry analysis in a cohort of consecutively enrolled NPC patients.
METHODS
A retrospective review of 154 NPC patients form our previous study (BMC Cancer. 2013; 13:226) were conducted. Survival and prognostic impacts were analyzed based on PD-L1, BRAF and EGFR expression levels.
RESULTS
One hundred fifty four patients were included in this study. PD-L1 expression was detected in 87.7% of patients; 14.3% had 1-5% PD-L1 expression, 47.4% had 5-49% expression while 26% had ≥50% expression Higher PD-L1 expression was significantly associated with shorter PFS and OS. The median PFS was 25 months (95% CI 15.7-34.3 months) and OS was 35 months (95% CI 22.60-47.4 months) for patients with PD-L1 expression ≥50%; both median PFS and OS were not yet reached for patients with PD-L1 expression < 50%. PFS was significantly higher in BRAF mutation positive patients (5-year PFS: 55.1% vs. 30.8%, P = 0.044).
CONCLUSION
Tumor PD-L1 expression and BRAF mutation are associated with poor outcomes in patients with NPC. This study was retrospectively registered in ClinicalTrials.gov (NCT03989297) on 2019-6-18.
背景
程序性死亡配体 1（PD-L1）和 BRAF 表达在鼻咽癌（NPC）中的预后价值尚未明确。在这项研究中，我们通过免疫组织化学分析，在一组连续入组的 NPC 患者中研究了 PD-L1、BRAF 和 EGFR 的改变。
方法
回顾性分析了来自我们之前研究（BMC Cancer. 2013; 13:226）的 154 例 NPC 患者。根据 PD-L1、BRAF 和 EGFR 的表达水平分析生存和预后的影响。
结果
本研究共纳入 154 例患者。PD-L1 表达在 87.7%的患者中被检测到；14.3%的患者 PD-L1 表达为 1-5%，47.4%的患者 PD-L1 表达为 5-49%，26%的患者 PD-L1 表达为≥50%。较高的 PD-L1 表达与较短的 PFS 和 OS 显著相关。PD-L1 表达≥50%的患者中位 PFS 为 25 个月（95%CI 15.7-34.3 个月），OS 为 35 个月（95%CI 22.60-47.4 个月）；而 PD-L1 表达<50%的患者中位 PFS 和 OS 均未达到。BRAF 突变阳性患者的 PFS 显著较高（5 年 PFS：55.1%比 30.8%，P=0.044）。
结论
肿瘤 PD-L1 表达和 BRAF 突变与 NPC 患者的不良预后相关。本研究于 2019 年 6 月 18 日在 ClinicalTrials.gov（NCT03989297）上进行了回顾性注册。
Zotero 插件